0000899243-20-024410.txt : 20200904
0000899243-20-024410.hdr.sgml : 20200904
20200904210655
ACCESSION NUMBER: 0000899243-20-024410
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200904
FILED AS OF DATE: 20200904
DATE AS OF CHANGE: 20200904
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CRAVES FRED B
CENTRAL INDEX KEY: 0001014095
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33277
FILM NUMBER: 201162812
MAIL ADDRESS:
STREET 1: 750 BATTERY ST
STREET 2: STE 600
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94111
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MADRIGAL PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001157601
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 BARR HARBOR DRIVE, SUITE 400
CITY: WEST CONSHOHOCKEN
STATE: PA
ZIP: 19428
BUSINESS PHONE: 404-380-9263
MAIL ADDRESS:
STREET 1: 200 BARR HARBOR DRIVE, SUITE 400
CITY: WEST CONSHOHOCKEN
STATE: PA
ZIP: 19428
FORMER COMPANY:
FORMER CONFORMED NAME: SYNTA PHARMACEUTICALS CORP
DATE OF NAME CHANGE: 20010815
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-09-04
0
0001157601
MADRIGAL PHARMACEUTICALS, INC.
MDGL
0001014095
CRAVES FRED B
C/O BAY CITY CAPITAL LLC,
750 BATTERY STREET, SUITE 400
SAN FRANCISCO
CA
94111
1
0
1
0
Common Stock
2020-09-04
4
J
0
1468350
0.00
D
2260791
I
See Footnotes
Common Stock
2020-09-04
4
J
0
31650
0.00
D
49730
I
See Footnotes
Common Stock
2020-09-04
4
J
0
45460
0.00
D
43537
I
See Footnotes
Common Stock
370016
D
Common Stock
90000
I
See Footnote
Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), Bay City Capital Fund IV, L.P., a Delaware limited partnership ("Fund IV"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment IV") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV.
These securities are held by Fund IV. Dr. Craves disclaims beneficial ownership of these securities held by Fund IV, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.
These securities are held by Co-Investment IV. Dr. Craves disclaims beneficial ownership of these securities held by Co-Investment IV, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.
These securities are held by BCC. Dr. Craves disclaims beneficial ownership of these securities held by BCC, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.
Represents shares held indirectly by Dr. Craves through a grantor retained annuity trust.
Represents transfers, without the payment of any consideration, to their partners and employees.
Includes 88,333 shares previously reported as indirectly held.
/s/ Fred B. Craves
2020-09-04